ABBV-974 is primarily investigated for its potential therapeutic applications in the field of oncology. It is being studied as a targeted therapy for specific types of cancers, particularly those driven by genetic mutations or protein dysregulation. The compound is designed to inhibit certain pathways or proteins that are critical for cancer cell survival and proliferation, thereby halting tumor growth or inducing cancer cell death. Preclinical and clinical trials are ongoing to evaluate its efficacy, safety, and optimal dosing in patients. If successful, it could offer a novel treatment option for patients with limited therapeutic alternatives, potentially improving outcomes in hard-to-treat cancers.